大剂量静脉丙种球蛋白防治毛细支气管炎发展为哮喘的临床研究

Clinical Study on Large Dose Intravenous Immunoglobulin in Decreasing Incidence of Asthma Following Bronchiolitis

目的探讨大剂量静脉丙种球蛋白（IVIG）对预防毛细支气管炎发展成哮喘的临床疗效。方法选择确诊为毛细支气管炎而采用不同治疗方案住院患儿196例，观察其5～10年后哮喘发病情况。随访168例。其中男132例，女36例；分为对照组87例，予常规治疗。大剂量IVIG组81例，在常规治疗基础上予IVIG 0．4g／（kg·d），连用5d。结果大剂量IVIG组81例，发生哮喘17例，占20．99％；常规治疗组87例，发生哮喘46例，占52．87％，两组哮喘发生率比较，有显著差异（P〈0．01）。结论大剂量IVIG能有效降低毛细支气管炎日后哮喘的发生率。

Objective To study the efficiency of large dose intravenous immunoglobulin （IVIG） in decreasing incidence of asthma following bronchiolitis. Methods One hundred and sixty - eight children with bronchiolitis were chosen to use different treatment plans, 81 children receiving large dose of IVIG[ 0.4 g/（kg· d） ] daily,on the basis of routine treatment for 5 days, while other 87 children were reserved as control group receiving routine treatment only, which were followed up 5 to 10 years. Results After following up 5 to 10 years, only 17 eases in 81 patients with bronchiolitis receiving large dose IVIG developed into asthma. However , 46 eases in control group developed into asthma. The incidence of asthma was 20.99 % and 52.87 % in two groups, respectively, showing significant difference between them（ P 〈 0.01 ）. Conclusion Large dose IVIG can decrease the incidence of asthma following bronchiolitis.